8-K: Zimmer Biomet Announces $1.75 Billion Notes Offering

Zimmer Biomet Holdings, Inc. has entered into an underwriting agreement for a public offering of $1.75 billion in aggregate principal amount of notes due in 2027, 2030, and 2035.

Summary

• Zimmer Biomet Holdings, Inc. has announced a public offering of $1.75 billion in notes.
• The offering includes $600 million of 4.700% notes due 2027, $550 million of 5.050% notes due 2030, and $600 million of 5.500% notes due 2035.
• The sale of the notes is expected to close on February 19, 2025, subject to customary closing conditions.
• The company intends to use the net proceeds from the sale of the notes for general corporate purposes.
• Goldman Sachs & Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and SMBC Nikko Securities America, Inc. are acting as representatives of the underwriters for the offering.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company is raising capital through a debt offering, which is a common financial activity. The terms of the offering appear standard, and there are no immediate red flags.

Positives

• The offering provides Zimmer Biomet with access to capital markets to raise $1.75 billion.
• The company has locked in fixed interest rates for the next several years.
• The underwriting agreement includes customary terms and conditions, suggesting a standard transaction.

Negatives

• The company will incur additional debt, which could increase its financial leverage.
• The company is subject to market risks and uncertainties that could affect its ability to repay the debt.
• The company is subject to customary closing conditions, and there is no guarantee that the sale of the notes will close.

Risks

• The closing of the offering is subject to customary closing conditions, and may not occur.
• The company's intended use of proceeds is subject to change.
• The forward-looking statements are subject to risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially.

Future Outlook

The company intends to use the net proceeds from the sale of the notes for general corporate purposes.

Industry Context

This announcement reflects a common practice in the healthcare industry, where companies often raise capital through debt offerings to fund acquisitions, research and development, or general corporate purposes.

Comparison to Industry Standards

• Comparable companies such as Medtronic, Stryker, and Johnson & Johnson frequently utilize debt financing as part of their capital structure.
• The interest rates on the notes are within the typical range for corporate debt offerings with similar maturities and credit ratings.
• The size of the offering is consistent with other large-cap medical device companies.

Related Party Transactions

• The Underwriters and their affiliates are full service financial institutions that have engaged in, and may in the future engage in, commercial banking, financial advisory, investment banking, lending and other commercial dealings in the ordinary course of their business with the Company or its affiliates, including participating as lenders under the Company's credit facilities, for which they have received, and may in the future receive, customary fees and commissions.
• Goldman Sachs & Co. LLC has acted as the Company's exclusive financial advisor with respect to that certain agreement and plan of merger between the Company, its subsidiary Zimmer, Inc., its subsidiary Gazelle Merger Sub I, Inc. and Paragon 28, Inc. (Paragon 28), pursuant to which Gazelle Merger Sub I, Inc. will merge with and into Paragon 28, with Paragon 28 continuing as the surviving corporation and an indirect wholly-owned subsidiary of the Company, and Goldman Sachs & Co. LLC will receive customary fees, expense reimbursement and indemnification in connection with such engagement.
• Certain of the Underwriters or their affiliates are holders of the Company's 3.550% notes due 2025 (the 2025 Notes), and/or have short positions in the 2025 Notes, and will receive their proportionate share of the net proceeds from the offering of the Notes to the extent they hold 2025 Notes at such time and such proceeds are used to redeem or otherwise retire a portion of the 2025 Notes or to repay a portion of the 2025 Notes at maturity.

Stakeholder Impact

• Shareholders: The debt offering could impact the company's financial leverage and potentially affect shareholder value.
• Employees: The use of proceeds for general corporate purposes could support future growth and job security.
• Creditors: The new notes will increase the company's debt obligations.
• Customers: The offering itself is unlikely to have a direct impact on customers.

Next Steps

• The sale of the notes is scheduled to close on February 19, 2025, subject to customary closing conditions.
• The company will file a final prospectus supplement with the SEC.
• The company will use the net proceeds from the sale of the notes for general corporate purposes.

Key Dates